{"id":"https://openalex.org/W2945823283","doi":"https://doi.org/10.1186/s12885-019-5569-5","title":"Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis","display_name":"Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis","publication_year":2019,"publication_date":"2019-04-15","ids":{"openalex":"https://openalex.org/W2945823283","doi":"https://doi.org/10.1186/s12885-019-5569-5","mag":"2945823283","pmid":"https://pubmed.ncbi.nlm.nih.gov/30987609","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6466705"},"language":"en","primary_location":{"id":"doi:10.1186/s12885-019-5569-5","doi":"https://doi.org/10.1186/s12885-019-5569-5","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s12885-019-5569-5","pdf_url":"https://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-019-5569-5","source":{"id":"https://openalex.org/S192926780","display_name":"BMC Cancer","issn_l":"1471-2407","issn":["1471-2407"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMC Cancer","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-019-5569-5","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5024693826","display_name":"Adrian D. Vickers","orcid":"https://orcid.org/0000-0003-0304-1951","observed_orcids":["https://orcid.org/0000-0003-0304-1951"]},"institutions":[{"id":"https://openalex.org/I4210120329","display_name":"RTI Health Solutions","ror":"https://ror.org/032nh7f71","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670","https://openalex.org/I4210120329"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Adrian D. Vickers","raw_affiliation_strings":["RTI Health Solutions, The Pavilion, Towers Business Park, Wilmslow Road, Didsbury, Manchester, M20 2LS, UK. avickers@rti.org","RTI Health Solutions, The Pavilion, Towers Business Park, Wilmslow Road, Didsbury, Manchester, M20 2LS, UK"],"raw_orcid":"https://orcid.org/0000-0003-0304-1951","affiliations":[{"raw_affiliation_string":"RTI Health Solutions, The Pavilion, Towers Business Park, Wilmslow Road, Didsbury, Manchester, M20 2LS, UK. avickers@rti.org","institution_ids":["https://openalex.org/I4210120329"]},{"raw_affiliation_string":"RTI Health Solutions, The Pavilion, Towers Business Park, Wilmslow Road, Didsbury, Manchester, M20 2LS, UK","institution_ids":["https://openalex.org/I4210120329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090793200","display_name":"Katherine B. Winfree","orcid":"https://orcid.org/0000-0003-2088-1004","observed_orcids":["https://orcid.org/0000-0003-2088-1004"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Katherine B. Winfree","raw_affiliation_strings":["Eli Lilly and Company Limited, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company Limited, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031548464","display_name":"Gebra Cuy\u00fan Carter","orcid":"https://orcid.org/0000-0002-6549-0069","observed_orcids":["https://orcid.org/0000-0002-6549-0069"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gebra Cuyun Carter","raw_affiliation_strings":["Eli Lilly and Company Limited, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company Limited, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087472457","display_name":"Urpo Kiiskinen","orcid":"https://orcid.org/0000-0003-0791-940X","observed_orcids":["https://orcid.org/0000-0003-0791-940X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Urpo Kiiskinen","raw_affiliation_strings":["Eli Lilly and Company Limited, Helsinki, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company Limited, Helsinki, Finland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071015984","display_name":"Min\u2010Hua Jen","orcid":"https://orcid.org/0000-0002-4916-0107","observed_orcids":["https://orcid.org/0000-0002-4916-0107"]},"institutions":[{"id":"https://openalex.org/I4210095227","display_name":"Eli Lilly (United Kingdom)","ror":"https://ror.org/00psab413","country_code":"GB","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210095227"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Min-Hua Jen","raw_affiliation_strings":["Eli Lilly and Company Limited, Windlesham, Surrey, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company Limited, Windlesham, Surrey, UK","institution_ids":["https://openalex.org/I4210095227"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090512389","display_name":"Donald E. Stull","orcid":"https://orcid.org/0000-0001-9808-5417","observed_orcids":["https://orcid.org/0000-0001-9808-5417"]},"institutions":[{"id":"https://openalex.org/I4210120329","display_name":"RTI Health Solutions","ror":"https://ror.org/032nh7f71","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670","https://openalex.org/I4210120329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Donald Stull","raw_affiliation_strings":["RTI Health Solutions, Research Triangle Park, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"RTI Health Solutions, Research Triangle Park, NC, USA","institution_ids":["https://openalex.org/I4210120329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069970576","display_name":"James A. Kaye","orcid":"https://orcid.org/0000-0002-9357-4227","observed_orcids":["https://orcid.org/0000-0002-9357-4227"]},"institutions":[{"id":"https://openalex.org/I4210120329","display_name":"RTI Health Solutions","ror":"https://ror.org/032nh7f71","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670","https://openalex.org/I4210120329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James A. Kaye","raw_affiliation_strings":["RTI Health Solutions, Waltham, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"RTI Health Solutions, Waltham, MA, USA","institution_ids":["https://openalex.org/I4210120329"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5059652753","display_name":"David Paul Carbone","orcid":"https://orcid.org/0000-0003-3002-1921","observed_orcids":["https://orcid.org/0000-0003-3002-1921"]},"institutions":[{"id":"https://openalex.org/I2802841970","display_name":"The Ohio State University Wexner Medical Center","ror":"https://ror.org/00c01js51","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2802841970"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David P. Carbone","raw_affiliation_strings":["Ohio State University Medical Center, Columbus, OH, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ohio State University Medical Center, Columbus, OH, USA","institution_ids":["https://openalex.org/I2802841970"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5024693826"],"corresponding_institution_ids":["https://openalex.org/I4210120329"],"apc_list":{"value":2390,"currency":"USD","value_usd":2390},"apc_paid":{"value":2390,"currency":"USD","value_usd":2390},"fwci":0.8854,"has_fulltext":true,"cited_by_count":34,"citation_normalized_percentile":{"value":0.69111724,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"19","issue":"1","first_page":"353","last_page":"353"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.0015999999595806003,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.890999972820282},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.8500000238418579},{"id":"https://openalex.org/keywords/docetaxel","display_name":"docetaxel","score":0.9729999899864197},{"id":"https://openalex.org/keywords/ramucirumab","display_name":"ramucirumab","score":0.9929999709129333},{"id":"https://openalex.org/keywords/nintedanib","display_name":"nintedanib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.9739999771118164},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.9850000143051147},{"id":"https://openalex.org/keywords/gefitinib","display_name":"gefitinib","score":1.0},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.9950000047683716},{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.9350000023841858},{"id":"https://openalex.org/keywords/egfr-mutation","display_name":"EGFR mutation","score":0.9940000176429749},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.7870000004768372},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8069999814033508},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9980000257492065}],"concepts":[{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.9194848537445068},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.8538500666618347},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8304712772369385},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.7614387273788452},{"id":"https://openalex.org/C2779551604","wikidata":"https://www.wikidata.org/wiki/Q7290345","display_name":"Ramucirumab","level":3,"score":0.7293065190315247},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7085504531860352},{"id":"https://openalex.org/C2909325608","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib Hydrochloride","level":5,"score":0.530802309513092},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.5210570693016052},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.5072647929191589},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.4746556878089905},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.45760369300842285},{"id":"https://openalex.org/C2779177807","wikidata":"https://www.wikidata.org/wiki/Q3658562","display_name":"non-small cell lung cancer (NSCLC)","level":4,"score":0.45634424686431885},{"id":"https://openalex.org/C2777626846","wikidata":"https://www.wikidata.org/wiki/Q21506464","display_name":"Osimertinib","level":5,"score":0.4241049587726593},{"id":"https://openalex.org/C2776907518","wikidata":"https://www.wikidata.org/wiki/Q1734165","display_name":"Performance status","level":3,"score":0.42152857780456543},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4209756851196289},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.36730220913887024},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.31714099645614624},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.19170719385147095},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.15782228112220764},{"id":"https://openalex.org/C81729549","wikidata":"https://www.wikidata.org/wiki/Q4649475","display_name":"A549 cell","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014408","descriptor_name":"Biomarkers, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016016","descriptor_name":"Proportional Hazards Models","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019233","descriptor_name":"Retreatment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019468","descriptor_name":"Disease Management","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.1186/s12885-019-5569-5","doi":"https://doi.org/10.1186/s12885-019-5569-5","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s12885-019-5569-5","pdf_url":"https://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-019-5569-5","source":{"id":"https://openalex.org/S192926780","display_name":"BMC Cancer","issn_l":"1471-2407","issn":["1471-2407"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMC Cancer","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:5458322","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6466705","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:6466705","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6466705","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMC Cancer","raw_type":"Text"},{"id":"pmid:30987609","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30987609","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMC cancer","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:372369967d9c4a9cb9d9327001d909f8","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/372369967d9c4a9cb9d9327001d909f8","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"BMC Cancer, Vol 19, Iss 1, Pp 1-16 (2019)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1186/s12885-019-5569-5","doi":"https://doi.org/10.1186/s12885-019-5569-5","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s12885-019-5569-5","pdf_url":"https://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-019-5569-5","source":{"id":"https://openalex.org/S192926780","display_name":"BMC Cancer","issn_l":"1471-2407","issn":["1471-2407"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMC Cancer","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/systematic-review","display_name":"Systematic Review"},{"id":"https://openalex.org/study-designs/meta-analysis","display_name":"Meta-Analysis"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320324142","display_name":"European Society for Medical Oncology","ror":"https://ror.org/03xtz2n86"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2945823283.pdf","grobid_xml":"https://content.openalex.org/works/W2945823283.grobid-xml"},"referenced_works_count":78,"referenced_works":["https://openalex.org/W68436435","https://openalex.org/W412930461","https://openalex.org/W1523764380","https://openalex.org/W1571650151","https://openalex.org/W1839238860","https://openalex.org/W1870145217","https://openalex.org/W1896828031","https://openalex.org/W1902576439","https://openalex.org/W1964238015","https://openalex.org/W1966714873","https://openalex.org/W1974280424","https://openalex.org/W1982967337","https://openalex.org/W1995644960","https://openalex.org/W1999130958","https://openalex.org/W1999391077","https://openalex.org/W2010699829","https://openalex.org/W2018922262","https://openalex.org/W2019331695","https://openalex.org/W2022950401","https://openalex.org/W2040318364","https://openalex.org/W2045565957","https://openalex.org/W2051676630","https://openalex.org/W2053432470","https://openalex.org/W2059573268","https://openalex.org/W2059862833","https://openalex.org/W2064468398","https://openalex.org/W2081330516","https://openalex.org/W2087656788","https://openalex.org/W2097026987","https://openalex.org/W2097254028","https://openalex.org/W2099071272","https://openalex.org/W2104347254","https://openalex.org/W2111999709","https://openalex.org/W2113229858","https://openalex.org/W2117316096","https://openalex.org/W2118002846","https://openalex.org/W2118281867","https://openalex.org/W2119231744","https://openalex.org/W2122553809","https://openalex.org/W2123857987","https://openalex.org/W2129904284","https://openalex.org/W2130652363","https://openalex.org/W2134667653","https://openalex.org/W2139939379","https://openalex.org/W2140980839","https://openalex.org/W2142809967","https://openalex.org/W2144180913","https://openalex.org/W2144330816","https://openalex.org/W2144625636","https://openalex.org/W2144937265","https://openalex.org/W2147075384","https://openalex.org/W2148534890","https://openalex.org/W2148718427","https://openalex.org/W2149603665","https://openalex.org/W2155063211","https://openalex.org/W2156353875","https://openalex.org/W2163351155","https://openalex.org/W2170030318","https://openalex.org/W2170568643","https://openalex.org/W2198093519","https://openalex.org/W2255913386","https://openalex.org/W2293531514","https://openalex.org/W2321693269","https://openalex.org/W2336422553","https://openalex.org/W2337836619","https://openalex.org/W2406237357","https://openalex.org/W2468604051","https://openalex.org/W2489765770","https://openalex.org/W2560367415","https://openalex.org/W2572174216","https://openalex.org/W2588675203","https://openalex.org/W2598936606","https://openalex.org/W2600313033","https://openalex.org/W2605110940","https://openalex.org/W2916080668","https://openalex.org/W4230795615","https://openalex.org/W4238414078","https://openalex.org/W6830742364"],"related_works":["https://openalex.org/W2767143738","https://openalex.org/W2883058590","https://openalex.org/W4410822114","https://openalex.org/W2143654577","https://openalex.org/W2113229858","https://openalex.org/W2945103009","https://openalex.org/W4313857758","https://openalex.org/W6964157694","https://openalex.org/W2411232948","https://openalex.org/W6902374187"],"abstract_inverted_index":{"BACKGROUND:":[0],"Locally":[1],"advanced":[2],"or":[3,47],"metastatic":[4],"non-small":[5],"cell":[6],"lung":[7],"cancer":[8],"(NSCLC)":[9],"that":[10],"has":[11,16],"progressed":[12],"after":[13],"first-line":[14],"treatment":[15,192],"a":[17,53,154,166,200,271],"poor":[18],"prognosis.":[19],"Recent":[20],"randomized":[21],"clinical":[22],"trials":[23],"(RCTs)":[24],"have":[25],"demonstrated":[26],"survival":[27,114,118,129],"benefits":[28],"of":[29,60,181,211,239,266,277,280],"alternative":[30],"treatments":[31,62,289],"to":[32,107,126,153,160,173,208,220,274,290],"docetaxel.":[33],"However,":[34],"information":[35],"is":[36,49,307],"lacking":[37],"on":[38,149],"which":[39],"patients":[40,292],"benefit":[41],"the":[42,91,140,145,161,178,225,246,256,264,278],"most":[43],"and":[44,56,76,96,116,131,205,234,245,298],"what":[45],"drug":[46],"regimen":[48],"optimal.":[50],"We":[51],"report":[52],"systematic":[54],"review":[55,306],"network":[57,180],"meta-analysis":[58],"(NMA)":[59],"second-line":[61],"in":[63,203,224,241,255,309],"all":[64],"subgroup":[65],"combinations":[66],"determined":[67],"by":[68,286,294],"histology,":[69,295],"programmed":[70],"death":[71],"ligand":[72],"1":[73],"(PD-L1)":[74],"expression,":[75,297],"epidermal":[77],"growth":[78],"factor":[79],"receptor":[80],"(EGFR)":[81],"mutation.":[82],"METHODS:":[83],"MEDLINE,":[84],"PubMed,":[85],"EMBASE,":[86],"Biosciences":[87],"Information":[88],"Service":[89],"(using":[90],"Dialog":[92],"Platform),":[93],"Cochrane":[94],"Library,":[95],"abstracts":[97],"from":[98],"scientific":[99],"meetings":[100],"were":[101,112,124],"searched":[102],"for":[103,134,177],"RCTs":[104],"published":[105],"up":[106],"September":[108],"2015.":[109],"Key":[110],"outcomes":[111],"overall":[113],"(OS)":[115],"progression-free":[117],"(PFS).":[119],"Bayesian":[120],"hierarchical":[121],"exchangeable":[122],"NMAs":[123],"conducted":[125],"calculate":[127],"mean":[128],"times":[130],"relative":[132,207],"differences":[133],"eight":[135],"subgroups,":[136],"using":[137],"docetaxel":[138,221],"as":[139],"reference":[141,162],"comparator.":[142],"For":[143,164],"OS,":[144],"NMA":[146],"was":[147,171,197],"based":[148],"hazard":[150],"ratios":[151],"applied":[152],"first-order":[155],"fractional":[156,168],"polynomial":[157,169],"model":[158,170],"fitted":[159,172],"treatment.":[163,282],"PFS,":[165,206],"second-order":[167],"reconstructed":[174],"patient-level":[175],"data":[176],"entire":[179],"evidence.":[182],"RESULTS:":[183],"The":[184],"search":[185],"identified":[186],"30":[187],"studies":[188],"containing":[189],"17":[190],"different":[191],"regimens.":[193],"Docetaxel":[194,214],"plus":[195,215,222],"ramucirumab":[196,223],"associated":[198],"with":[199],"significant":[201],"improvement":[202],"OS":[204],"docetaxel,":[209],"regardless":[210],"patient":[212],"type.":[213],"nintedanib":[216],"showed":[217,236,252],"similar":[218],"efficacy":[219,240,254,279],"nonsquamous":[226],"populations.":[227],"EGFR":[228,242,299],"tyrosine":[229],"kinase":[230],"inhibitors":[231],"(TKIs)":[232],"erlotinib":[233],"gefitinib":[235],"superior":[237,253],"levels":[238],"mutation-positive":[243],"populations":[244,257],"one":[247],"PD-1":[248],"immunotherapy":[249],"(nivolumab)":[250],"studied":[251],"exhibiting":[258],"high":[259],"PD-L1":[260,296],"expression.":[261],"CONCLUSIONS:":[262],"In":[263],"absence":[265],"head-to-head":[267],"comparisons,":[268],"we":[269],"performed":[270],"mixed-treatment":[272],"analysis":[273],"synthesize":[275],"evidence":[276],"each":[281],"Benefits":[283],"are":[284],"optimized":[285],"targeting":[287],"specific":[288],"individual":[291],"guided":[293],"mutation":[300],"status.":[301],"SYSTEMATIC":[302],"REVIEW":[303],"REGISTRATION:":[304],"This":[305],"registered":[308],"PROSPERO":[310],"(registration":[311],"number:":[312],"CRD42014013780":[313],"available":[314],"at":[315],"www.crd.york.ac.uk/PROSPERO":[316],").":[317]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":9},{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2019-05-29T00:00:00"}